论文部分内容阅读
目的:评价重组人干扰素-α2b阴道泡腾片对宫颈高危人乳头瘤病毒(Human papilloma virus,以下简称HPV)感染患者HPV转阴的临床疗效及其安全性。方法:选取医院2015年8月—2016年3月期间收治的宫颈高危HPV感染患者90例临床资料,将其随机分为治疗组和参照组,每组45例;治疗组患者给予重组人干扰素-α2b阴道泡腾片治疗,参照组患者给予不含重组人干扰素-α2b的阴道泡腾片治疗,比较两组患者用药后HPV转阴情况和用药期间不良反应的发生情况。结果:治疗后对两组患者随访1年,发现治疗3、6和9月时,治疗组患者的HPV转阴率均高于参照组(P<0.05);治疗12月时,两组患者的HPV转阴率经比较其差异无统计学意义(P>0.05);两组患者治疗期间均未发生不良反应症状。结论:重组人干扰素-α2b阴道泡腾片用于治疗宫颈高危HPV感染患者,对治疗不同时段(3、6和9月)的HPV转阴率均得到明显改善,且安全性较高。
Objective: To evaluate the clinical efficacy and safety of recombinant human interferon-α2b vaginal effervescent tablet in the treatment of HPV negative in patients with high-risk human papilloma virus (HPV) infection. Methods: The clinical data of 90 cases of high risk HPV infection from cervix in our hospital from August 2015 to March 2016 were selected and randomly divided into treatment group and reference group, 45 cases in each group. The patients in treatment group were given recombinant human interferon -α2b vaginal effervescent tablets treatment, the reference group of patients given without recombinant human interferon-α2b vaginal effervescent tablets treatment, the two groups of patients after treatment of HPV negative and drug adverse reactions during the occurrence of adverse reactions. Results: The two groups of patients were followed up for 1 year after treatment. The incidence of HPV negative conversion in the treatment group was significantly higher than that of the reference group (P <0.05) at 3, 6 and 9 months. At 12 months, There was no significant difference in HPV negative conversion rate between the two groups (P> 0.05). No adverse reaction symptoms occurred in the two groups during treatment. CONCLUSION: The recombinant human interferon-α2b vaginal effervescent tablet can be used to treat patients with high-risk HPV infection. The HPV negative conversion rate in different periods (3, 6 and 9 months) of treatment is significantly improved and the safety is high.